Story perspectives

MIT and Harvard Develop Safer CAR-NK Cells for Cancer

10/12/2025

Summary

Story summary

Massachusetts Institute of Technology (MIT) and Harvard Medical School researchers have developed a method to engineer chimeric antigen receptor natural killer cells (CAR-NK) that increases cancer-fighting effectiveness while reducing immune rejection.
The approach enables rapid production of off-the-shelf CAR-NK treatments and shows in mouse studies that the cells targeted and eliminated cancer with a safer profile than CAR-T therapies.
The team plans clinical trials and will explore lupus applications.

1 of 1

Story summary

Massachusetts Institute of Technology (MIT) and Harvard Medical School researchers have developed a method to engineer chimeric antigen receptor natural killer cells (CAR-NK) that increases cancer-fighting effectiveness while reducing immune rejection.
The approach enables rapid production of off-the-shelf CAR-NK treatments and shows in mouse studies that the cells targeted and eliminated cancer with a safer profile than CAR-T therapies.
The team plans clinical trials and will explore lupus applications.